Introduction
Acetylcholine (ACh) pathways regulate a variety of cognitive, motor, and autonomic functions. Dysfunction of ACh pathways is implicated in Alzheimer's disease and Parkinson's disease. Under many physiological conditions, the biosynthesis and release of ACh are controlled by the availability of precursor, choline (Yamamura and Snyder, 1972; Jope, 1979; Jope and Jenden, 1980; Blusztajn and Wurtman, 1983) . Therefore, a more thorough understanding of cellular mechanisms controlling choline transport in cholinergic neurons may provide insights into pathophysiology and drug therapy of diseases associated with cholinergic dysfunction.
In cholinergic neurons, a distinct hemicholinium-3 (HC-3) sensitive, Na + /Cl --dependent choline transporter (CHT) provides choline for ACh synthesis (Okuda and Haga, 2000; Okuda et al., 2000; Apparsundaram et al., 2000; Apparsundaram et al., 2001; Okuda and Haga, 2003; Ferguson and Blakely, 2004) . CHT mediates high-affinity choline uptake, a process considered to be rate-limiting in ACh synthesis, and a potential target for modulating cholinergic function (Knipper et al., 1992; Okuda and Haga, 2000; Okuda et al., 2000; Apparsundaram et al., 2000; Apparsundaram et al., 2001; Okuda and Haga, 2003; Ferguson and Blakely, 2004) . Disruption of CHT in mice is lethal to neonates (Randy Blakely, unpublished observation) further validates However, the mechanisms underlying these effects have not been studied thoroughly. Recent studies of Na + and Cl -dependent neurotransmitter transporters, including dopamine, norepinephrine, and serotonin, reveal PKC and PP1/PP2A regulate these transporter proteins via rapid changes in transporter surface expression and phosphorylation (Torres et al., 2003) .
The presence of consensus PKC, serine/threonine phosphorylation sites in CHT protein provides a compelling possibility that changes in phosphorylation state may be involved in CHT regulation (Okuda and Haga, 2000; Apparsundaram et al., 2001) . Recent findings also revealed the localization of CHT protein in multiple compartments, including the plasma membrane, a subpopulation of synaptic vesicles and endosomal vesicles (Ferguson et al., 2003; Ribeiro et al., 2003; Ferguson and Blakely, 2004) . These observations suggest that CHT may also be potentially regulated via changes in CHT distribution. Indeed, previous studies in locust brain synaptosomes (Knipper et al., 1992) , and Limulus brain slices (Ford et al., 1999) have reported protein kinase C (PKC)-mediated alterations in CHT function. In parallel studies using HC-3 binding, these investigators also showed that PKC activation alters the surface redistribution of CHT proteins (Knipper et al., 1992; Ford et al., 1999) . Besides PKC, protein phosphatase 1/2A (PP1/PP2A) inhibitors, calyculin A and okadaic acid, also displayed specific and profound inhibitory effects on high-affinity choline uptake (Issa et al., 1996) . The focus of the present study is to determine the influence of PKC and protein phosphatases on CHT function, surface distribution, and phosphorylation in the mouse brain.
The availability of CHT specific antibodies which recognizes CHT proteins in mammalian tissues (Ferguson et al., 2003; Kus et al., 2003) , present new opportunities for investigating whether or not such regulatory mechanisms control CHT function. Our studies reveal that (1) CHT is a phosphoprotein, and (2) PKC and PP1/PP2A may influence CHT function via changes 6 in CHT surface distribution. These changes in CHT phosphorylation and surface distribution could have profound effects on the intensity and duration of cholinergic synaptic transmission.
This article has not been copyedited and formatted. The final version may differ from this version. weight, 8-10 weeks old, mice (The Jackson Laboratory, Bar Habor, ME) were decapitated under chloral hydrate anesthesia (0.4g/kg dose/intraperitoneal administration). The brains were removed under anesthesia, and partially dissected into 1 mm sections using a rodent brain matrix.
The hippocampus and striatum were isolated on an ice-cold petri dish, under a dissecting microscope. Isolated tissues were homogenized in ice-cold 0.32 M sucrose using glass homogenizer with teflon pestle (clearance 0.1mm), 8 strokes, at 2500 rpm (Wheaton oberhead strirrer). The homegenate was spun at 1000 x g for 15 min. The resulting supernatant was spun at 12,500 x g for 15 min and the pellet containing synaptosomes was suspended in Kreb's bicarbonate buffer (KBB) containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 , Na 2 EDTA, 1.7 mM CaCl 2 , 10 mM glucose, and supplemented with 100 µM ascorbic acid and 10 µM physostigmine, and bubbled with 95:5 mixture of O 2 :CO 2 . Aliquots (10 µl) of crude synaptosomal suspension were used for protein determination using the Bradford Method (Bio-Rad).
Choline Transport Assays
For choline transport assays, aliquots (50 µl) of the synaptosomal suspension, typically 30-50 µg protein, were incubated for 5 min at 37˚C in the presence and absence of 10 µM HC-3.
Then, synaptosomes were further incubated with the indicated modulating agent(s) at 37˚C for the indicated times. Choline transport was initiated by the addition of 0.1 ml of 100 nM [ 3 H]-choline and the incubation was continued for 5 min at 37˚ C. The incubation was stopped by transferring the tubes to an ice bath followed by rapid filtration using the Brandel filtration apparatus (Brandel Biomedical Research and Development Labatories, Gaithersburg, MD, USA). Kinetic studies were carried out using 1 nM to 5µM choline with ~ 5-20% labeled This article has not been copyedited and formatted. The final version may differ from this version. choline. Specific CHT-mediated choline uptake is defined as total choline uptake minus choline uptake in the presence of HC-3.
Determination of Plasma Membrane Associated Choline Transporter:
Biotinylation and Immunoblotting
We examined the plasma membrane content of CHT in crude synaptosomes using the membrane impermeant biotinylating reagent, sulfosuccinimidobiotin (NHS-Biotin) (Chi and Reith, 2003; Salvatore et al., 2003) . Crude synaptosomes (500 µg protein/tube) were incubated with specific modulating agent for 45 min at 37˚C, and washed 3 times with 1 ml ice-cold KBB to remove excess agent. Each wash step consists of centrifugation at 4˚C for 2min at 4000 X g with 1 ml of wash buffer. The tissue was then incubated in 500 µl of 1.5 mg/ml sulfosuccinimidobiotin for 1h at 4˚C, washed in ice-cold PBS/Ca/Mg buffer (138 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 9.6 mM Na 2 HPO 4 , 1 mM MgCl 2 , 0.1 mM CaCl 2 , pH 7.3). After washing away the biotinylating reagents, the pellet was resuspended and incubated for 30 min with ice-cold 100mM glycine (pH 3.0) in PBS/Ca/Mg buffer. Crude synaptosomes were again washed 3 times with PBS/Ca/Mg buffer and then lysed with 500 µl of radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% sodium dodecylsulfate (SDS), 1% Triton, 1% sodium deoxycholate), supplemented with protease inhibitors (1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml aprotinin, and 250 µM phenylmethylsulfonyl fluoride) and PP1/2A inhibitor, 10 µM OKA. The extracts were centrifuged at 21,000 x g at 4˚C. Aliquots (100 µl) of the extract were saved for immunoblotting of total CHT protein, while the remaining extracts were incubated with monomeric avidin beads (100 µl/tube) in the same buffer for 1 h at room temperature for the separation of biotinylated This article has not been copyedited and formatted. The final version may differ from this version. and non-biotinylated proteins. At the end of incubation period, the beads were separated by centrifugation and the beads were washed in lysis buffer 3 times, and proteins bound to avidin beads were eluted by incubating in 50 µl Laemmli buffer (62.5 mM Tris, pH 6.8, 20% glycerol, 2% SDS, and 5% bromophenol blue, supplemented with 5% β -mercaptoethanol) for 20 min at room temperature. In order to achieve complete separation of biotinylated proteins and nonbiotinylated proteins, bead incubation, centrifugation, and elution with Laemmli buffer were repeated with a second aliquot of avidin beads. The bead eleuents were combined and aliquots (60 µl) of total extract and bead eluents were used in SDS-PAGE for protein separation.
Seperated proteins were transferred to a PVDF membrane (Millipore Corporation; Bedford, MA, USA). The blots were incubated with the mouse monoclonal CHT antibody (1:1000) in phosphate-buffered saline (PBS)-Tween (0.5%) buffer containing 5% non-fat dry milk. The CHT-immunoreactive bands were detected using chemiluminscence (Amersham Pharmacia Biotech) and autoradiography (Hyperfilm; Amersham Pharmacia Biotech). After CHT detection, the blots were stripped (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM β -mercaptoethanol), and reprobed with rabbit polyclonal calnexin antibody (1:1000) or mouse monoclonal syntaxin 1A (1:3000) antibody. Calnexin determinations were carried out to monitor the extent of biotinylation of intracellular proteins by membrane impermeant NHS biotin, whereas syntaxin 1A determinations were carried out as controls for monitoring protein loading of fractions derived from either vehicle-or drug-treated synaptosomes. The band densities of specific bands were quantified using Scion image software (Scion Corporation: Frederick, MD, USA), and CHT protein band density in different fractions were normalized using syntaxin and calnexin band densities.
Metabolic Labeling and Immunoprecipation
Metabolic labeling of CHTs with 32 PO 4 in the mouse striatum was carried out as described previously with slight modifications (Halpain et al., 1990; Vaughan et al., 1997) . Mouse striatum was dissected out as described earlier, and then striatal sections were sliced (~50 µm x 50 µm x 50 µm slices) using the McElwain tissue chopper (Mickle Laboratory Engineering Co.
Inc, Surrey, UK). Slices equivalent to 300 µg protein were placed in tubes containing 1 ml of oxygenated phosphate-free KBB (25 mM NaHCO 3 , 125 mM NaCl, 5 mM KCl, 1.5 mM CaCl 2 , 5 mM MgSO 4 , and 10 mM glucose, pH 7.3), and incubated for 30 min at 37ºC with gentle shaking.
Slices were then incubated with fresh 1 ml phosphate-free KBB buffer containing 1mCi/ml 32 P labeled orthophosphate and the mixture incubated for 2 hr at 37ºC. Test compounds or vehicle were added over the final 45 min. At the end of the metabolic labeling, slices were washed 3 times with ice-cold phosphate-free KBB (1 ml per wash followed by centrifugation 8000 x g; 4˚C, 2 min). After the final wash, slices were solubilized in 400 µl of 1% Triton X-100 buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% Triton), supplemented with protease inhibitors (1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml aprotinin, and 250 µM phenylmethylsulfonyl fluoride) and PP1/2A inhibitor, 10 µM OKA with the aid of a Sonic dismembrator (Fisher; Pittsburgh, PA, USA). Extracts were centrifuged at 21,000 x g for 20 min, and the supernatants were pre-cleared with 3mg of Protein A sepharose beads (Amersham Pharmacia Biotech) and the pre-cleared extracts were incubated with 5 µl of preimmune or CHT immune serum or 10 µl of CHT monoclonal antibody at 4ºC for 16 hr. Antigen-antibody immune complexes were then separated using 3 mg protein A sepharose beads (1 hr; room temperature). Beads were washed 3 times with the lysis buffer and the bound proteins were eluted with 50 µl of Laemmli buffer (20 min, room temperature). Samples were electrophoresed in SDS-PAGE gels, and dried gels were subjected to autoradiography (Kodak Biomax film;
Rochester, NY, USA). CHT specific bands were detected and the band density quantified using Scion image software.
Data Analysis
Results 
Results

Activation of PKC reduces CHT function in the mouse hippocampus and striatum
To examine the influence of PKC activation on CHT, we analyzed the effect of PKC activator, β-PMA, on CHT-mediated choline uptake in the mouse crude hippocampal and striatal synaptosomes. β-PMA produces a time-and concentration-dependent decline in CHT-mediated choline uptake (Fig. 1 ). In the crude hippocampal synaptosomes, a significant reduction was seen with 1 µM β-PMA following a 30 min treatment (Fig. 1A) . In the crude striatal synaptosomes, a significant effect was seen beginning at 15 min of β-PMA (1 µM) with about 20±2% reduction at 45 min ( Fig 1B) . Phorbol ester, β-PDBU (1 µM; 45 min) also produced significant decreases in CHT-mediated choline uptake in the crude hippocampal (33±6% reduction, p<0.05) and striatal (38±7% reduction, p<0.05) synaptosomes. On the other hand, the inactive phorbol ester, α-PMA (1µM, 45 min) failed to alter CHT-mediated choline uptake in both crude hippocampal and striatal synaptosomes (Fig. 2) . Treatment of crude synaptosomes with staurosporine (1 µM; 45 min), a PKC inhibitor, did not reveal a significant change, but abolished β-PMA-mediated reduction in CHT function in both hippocampus and striatum (Fig. 2). A structurally distinct PKC inhibitor, calphostin C, also provided effects that are comparable to staurosporine (data not shown). Together, these results suggest that activation of PKC reduces CHT function in the mouse hippocampus and striatum.
Blockade of protein phosphatase PP1/PP2A reduces CHT function in the mouse hippocampus and striatum
We next examined the influence of ser/thr protein phosphatases on CHT function in the mouse crude hippocampal and striatal synaptosomes. Inhibitors of PP1/PP2A, OKA or CL-A, produced a concentration-dependent reduction in CHT function in the striatal synaptosomes ( synaptosomes in rats (Chi and Reith, 2003; Salvatore et al., 2003) . In the present study, we pretreated mouse crude striatal synaptosomes with vehicle or β -PMA (1 µM, 45 min), and subjected to biotinylation protocol (see methods). We isolated biotinylated proteins and determined CHT levels using transporter specific antibody (Fig. 4) . We also examined the levels of endoplasmic reticular protein, calnexin, and SNARE protein, syntaxin 1A (Fig. 4) . Calnexin determinations were carried out to monitor the extent of biotinylation of intracellular proteins by membrane impermeant NHS biotin, whereas syntaxin 1A determinations were carried as a marker for equal loading of protein fractions derived from either vehicle-or drug-treated synaptosomes. We calculated the level of CHT in total, biotinylated, and non-biotinylated fraction based band densities, protein loaded in the gel and protein recovery from avidin beads.
In vehicle-treated striatal synaptosomes, ~ 30% of total CHT protein was found in the biotinylated fraction. The biotinylated fraction may also include CHT proteins in broken plasma membranes that may be present in crude synaptosomal preparations, and therefore, the actual levels of surface CHT may be less than 30% of total CHT levels. These studies also revealed the presence of calnexin (about 10%) in the bead eluent reflecting the possibility that NHS-biotin may label a small fraction of intracellular proteins derived from broken cell bodies during homogenization or may access intracellular proteins via leak pathways.
Pretreatment of synaptosomes with β-PMA (10 µM; 45 min) produced over a ~ 30% reduction of CHT in the biotinylated fraction with no alteration of CHT levels in total lysates. In
We observed no difference in the levels of syntaxin 1A and calnexin in the biotinylated fractions suggesting selective reduction of CHT levels in bead eluents following β-PMA treatment. PKC inhibitor staurosporine failed to alter the levels of CHT in the total and biotinylated fraction.
This article has not been copyedited and formatted. The final version may differ from this version. However, staurosporine pretreatment abolished β-PMA-mediated reduction of CHT levels in the biotinylated fraction (Fig. 5 ).
In the mouse crude striatal synaptosomal preparations, PP1/PP2A inhibitors, OKA ( Fig.   6A ) and calyculin A (Fig. 6B ), also produced a significant reduction in CHT levels in the biotinylated fraction (OKA ~ 30% reduction) with no apparent change in total lysates (protein).
Together, these results provide evidence that PKC activation and PP1/PP2A inhibition reduce surface expression of CHT proteins with no significant change in the plasma membrane permeability, and accessibility to proteins in intracellular compartments.
PKC activation and protein phosphatase PP1/PP2A inhibition reduce Vmax of choline transport and Surface Distribution of CHT in the mouse hippocampus
In parallel with striatal synaptosomes, we also carried out experiments in hippocampal synaptosomes. Choline transport kinetic studies in hippocampal synaptosmes in the presence and absence of β-PMA (1 µM; 45 min), OKA (10 µM; 45 min), and CL-A (10 µM; 45 min) also revealed a reduction in the maximal transport capacity, with minimal change in Km for choline (Fig. 7A, and 7B) . Biotinylation and immunoblot studies also revealed a significant reduction in CHT-immunoreactivity in bead eluents following treatment with β-PMA (1 µM; 45 min), OKA (10 µM; 45 min), and CL-A (10 µM; 45 min). However, these treatments failed to alter the levels of CHT-immunoreactivity in total lysates (Fig. 7C, and 7D ).
Immunoprecipitation of phosphorylated CHT protein in the mouse hippocampus and striatum
To investigate whether or not changes in CHT function following PKC activation and PP1/PP2A inhibition is accompanied by changes in the levels of CHT phosphorylation, we metabolically labeled mouse striatal slices with 32 PO 4 in the presence or absence of β-PMA (1 This article has not been copyedited and formatted. The final version may differ from this version. We also examined the effect of either β -PMA or OKA alone on CHT phosphorylation in the mouse striatum. OKA produced a time-dependent increase in CHT phosphorylation levels in the striatal slices (Fig. 8B, top panel) . A marked increase in CHT phosphorylation was obtained following 30 and 45 min pretreatment with OKA (10 µM; 45 min) ( Fig. 8B ; top panel). OKAevoked increase in CHT phosphorylation levels were paralleled by a significant decrease in CHT-mediated choline uptake (Fig. 8B, bottom panel) . On the other hand, β -PMA (10 µM; 45 min) pretreatment alone failed to alter the basal levels of CHT phosphorylation ( significant reduction of CHT-mediated choline uptake in striatal slices (Fig. 8C, bottom panel) .
Moreover, co-application of β -PMA and OKA augmented CHT phosphorylation to levels that were comparable to the application of OKA alone (Fig. 8C) 
Discussion
Neurotransmitters, second messengers, drug treatments and neuronal activity have been shown to tightly regulate HC-3 sensitive choline transport (Guyenet et al., 1973; Barker, 1976; Murrin and Kuhar, 1976; Roskoski, 1978; Sherman et al., 1978; O'Regan and Collier, 1981; Lowenstein and Coyle, 1986; Cancela et al., 1995; Cooke and Rylett, 1997; Vogelsberg et al., 1997; Ford et al., 1999) . However, little is known about regulatory mechanisms that control choline transport function. Recent studies on neurotransmitter transporters, including the dopamine (DAT), norepinephrine (NET), and serotonin (SERT) transporters, reveal that transporters may undergo rapid internalization and recycling in response to changes in the activity of cellular protein kinases and phosphatases (Torres et al., 2003) . Such dynamic changes in transporter distribution are thought to be a key regulatory mechanism for spatial and temporal control of neurotransmitter concentrations at synapses. In conjunction, evidence has been steadily accumulating documenting changes in transporter phosphorylation via cellular kinases and phosphatases (Vaughan et al., 1997; Ramamoorthy et al., 1998; Foster et al., 2003; Torres et al., 2003) . Changes in transporter phosphorylation levels, in some cases, might be linked to changes in its surface distribution (Vaughan et al., 1997; Ramamoorthy et al., 1998; Foster et al., 2003; Torres et al., 2003) . The recent availability of monoclonal and polyclonal CHT specific antibodies enabled the investigation of changes in the surface distribution and phosphorylation levels of CHT in response to PKC and PP1/PP2A modulation. In the present study, we reveal that (1) the function of CHT is governed by neuronal PKC and PP1/PP2A, (2) both PKC and PP1/PP2A may be involved in establishing the plasma membrane levels of CHT, and (3) PP1/PP2A activity may determine the levels of CHT phosphorylation.
This article has not been copyedited and formatted. The final version may differ from this version. Recent studies reveal that CHT is primarily localized in cholinergic neurons, with only low levels of CHT in non-cholinergic and non-neuronal cells (Ferguson et al., 2003; Kus et al., 2003) . Therefore, changes in HC-3 sensitive choline transport in the mouse striatum and hippocampus that are reported in our investigation mainly reflect changes in the function of CHT proteins expressed in cholinergic neurons. Our findings that PKC activation and protein phosphatase 1/2A inhibition reduces CHT function in the mouse hippocampal and striatal synaptosomes are similar to the previous reports in the rat hippocampal slices (Issa et al., 1996) , mouse hippocampal synaptosomes (Cooke and Rylett, 1997) , and Limulus brain hemi-slices (Ford et al., 1999) . However, in contrast to the effects seen in Limulus brain hemi-slices (Ford et al., 1999) , blockade of PKC failed to alter basal choline transport in the mouse hippocampal and striatal synaptosomes (Fig. 2) . The differential effect of PKC inhibitors in the mouse and Limulus brain regions may be due to plausible differences in the levels/activity of PKC and protein phosphatase 1/2A activity on CHT in these tissues. Investigating the relationship between levels of PKC/ PP1/PP2A activity and CHT regulation would shed some insights into these tissue differences. Furthermore, in contrast to in vitro reductions of high-affinity choline uptake (Issa et al., 1996; Cooke and Rylett, 1997) Previous studies have shown changes in surface distribution of neurotransmitter transporters, using surface biotinylation approaches, in response to PKC and PP1/PP2A modulation (Qian et al., 1997; Pristupa et al., 1998; Daniels and Amara, 1999) . We attempted to examine the surface expression of CHTs using this surface biotinylation technique in crude synaptosomal preparations. The lack of significant change in the total CHT levels suggested the Biotinylated proteins were separated from total lysate using avidin beads. CHT-immunoreativity in the samples was detected using CHT specific antibody. Blots were then stripped and reprobed with rabbit polyclonal calnexin antibody or mouse monoclonal syntaxin 1A specific antibody.
Representative blots probed with CHT, calnexin and syntaxin 1A antibodies (A) and band density of CHT-immunoreactive bands (B) are shown. CHT-IR bands were quantified using Scion image software and presented as mean ± SEM values of three experiments (p<0.05).
Asterisk(s) indicates significant difference as compared to control (Student's t-test; p<0.05). , and biotinylated proteins were separated from total lysates using avidin beads.
CHT-immunoreactivity in total lysates and bead eluents were detected using mouse monoclonal CHT-specific antibody. Blots were then stripped and re-probed with rabbit polyclonal calnexin or mouse monoclonal syntaxin 1A specific antibody. Representative blots probed with CHT, calnexin, syntaxin 1A antibodies and band densities of CHT-immunoreactive bands are shown.
CHT-IR bands were quantified using Scion image software and presented as mean ± SEM values of three experiments (p<0.05). Asterisk(s) indicates significant difference as compared to control (Student's t-test; p<0.05). okadaic acid/10 µM calyculin A, crude synaptosomes were incubated with membrane impermeant NHS-biotin. After quenching the biotinylation reaction, tissues were extracted with lysis buffer (see methods). Biotinylated proteins were separated from total lysate using avidin beads. CHT-immunoreactivity present in the samples was detected using CHT specific antibody.
Band density of CHT-immunoreactive bands in total lysate (C), and bead eluents (D) are shown.
CHT-IR bands were quantified using Scion image software and presented as mean ± SEM values of three experiments (p<0.05). Asterisk(s) indicates significant difference as compared to control (Student's t-test; p<0.05). 
